Switch theme
Sign up to access all valuation multiples
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
1989
504
LTM Revenue $515M
LTM EBITDA $26.3M
$4.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medifast has a last 12-month revenue (LTM) of $515M and a last 12-month EBITDA of $26.3M.
In the most recent fiscal year, Medifast achieved revenue of $602M and an EBITDA of $15.6M.
Medifast expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medifast valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $515M | XXX | $602M | XXX | XXX | XXX |
| Gross Profit | $381M | XXX | $445M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $26.3M | XXX | $15.6M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| EBIT | $8.1M | XXX | $2.9M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | -$3.1M | XXX | $2.1M | XXX | XXX | XXX |
| Net Margin | -1% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medifast's stock price is $14.
Medifast has current market cap of $155M, and EV of $4.7M.
See Medifast trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7M | $155M | XXX | XXX | XXX | XXX | $0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medifast has market cap of $155M and EV of $4.7M.
Medifast's trades at 0.0x EV/Revenue multiple, and 0.3x EV/EBITDA.
Equity research analysts estimate Medifast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medifast has a P/E ratio of -49.6x.
See valuation multiples for Medifast and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $155M | XXX | $155M | XXX | XXX | XXX |
| EV (current) | $4.7M | XXX | $4.7M | XXX | XXX | XXX |
| EV/Revenue | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 0.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -49.6x | XXX | 74.0x | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedifast's last 12 month revenue growth is -25%
Medifast's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.9M for the same period.
Medifast's rule of 40 is -12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medifast's rule of X is -58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medifast and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -25% | XXX | -21% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | -118% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -12% | XXX | -23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Brillia Inc | XXX | XXX | XXX | XXX | XXX | XXX |
| Adore Beauty | XXX | XXX | XXX | XXX | XXX | XXX |
| Kogan.com | XXX | XXX | XXX | XXX | XXX | XXX |
| Temple & Webster | XXX | XXX | XXX | XXX | XXX | XXX |
| BIKE24 | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medifast acquired XXX companies to date.
Last acquisition by Medifast was XXXXXXXX, XXXXX XXXXX XXXXXX . Medifast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medifast founded? | Medifast was founded in 1989. |
| Where is Medifast headquartered? | Medifast is headquartered in United States of America. |
| How many employees does Medifast have? | As of today, Medifast has 504 employees. |
| Who is the CEO of Medifast? | Medifast's CEO is Mr. Daniel R. Chard. |
| Is Medifast publicy listed? | Yes, Medifast is a public company listed on NYS. |
| What is the stock symbol of Medifast? | Medifast trades under MED ticker. |
| When did Medifast go public? | Medifast went public in 1981. |
| Who are competitors of Medifast? | Similar companies to Medifast include e.g. Brillia Inc, Adore Beauty, Kogan.com, Temple & Webster. |
| What is the current market cap of Medifast? | Medifast's current market cap is $155M |
| What is the current revenue of Medifast? | Medifast's last 12 months revenue is $515M. |
| What is the current revenue growth of Medifast? | Medifast revenue growth (NTM/LTM) is -25%. |
| What is the current EV/Revenue multiple of Medifast? | Current revenue multiple of Medifast is 0.0x. |
| Is Medifast profitable? | Yes, Medifast is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medifast? | Medifast's last 12 months EBITDA is $26.3M. |
| What is Medifast's EBITDA margin? | Medifast's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Medifast? | Current EBITDA multiple of Medifast is 0.2x. |
| What is the current FCF of Medifast? | Medifast's last 12 months FCF is $29.9M. |
| What is Medifast's FCF margin? | Medifast's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Medifast? | Current FCF multiple of Medifast is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
